Resp Res
-
Randomized Controlled Trial Multicenter Study
Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study).
Riociguat is a soluble guanylate cyclase stimulator approved for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTPEH). The objective of this study was to evaluate right heart size and function assessed by echocardiography during long term treatment with riociguat. ⋯ Patients under long-term treatment with riociguat show significantly reduced right heart size and improved RV function in PAH and CTEPH. Further controlled prospective studies are needed to confirm these results.
-
Multicenter Study
The impact of outdoor air pollutants on outpatient visits for respiratory diseases during 2012-2016 in Jinan, China.
Few studies have investigated the associations between outdoor air pollution and outpatient visits for respiratory diseases (RDs) in general population. ⋯ Exposure to outdoor air pollutants including PM2.5, PM10, NO2, CO and O3 associated with increased risk of outpatient visits for RDs.